BREAKING: Target Test Prep releases Brand New 2026 On Demand GMAT prep course

Redeem

Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

★★★★★5.0559 reviews
Vote for Target Test Prep, Newsweek Readers’ Choice Awards 2026
NEWSWEEK READERS’ CHOICE 2026

BIG NEWS! Target Test Prep has been nominated, and they’d love your vote!

TTP has worked incredibly hard to build the best test prep experience possible, and winning Newsweek’s 2026 Readers’ Choice Award for Best Test Prep would mean a lot to them. If TTP has helped you, they’d be incredibly grateful for your vote. You can vote once each day through September 9.

Vote for TTP
GMATLiveTeach 7 seats left
Chris Peckover
NEXT LIVE COHORT

Oct 13 to Jan 7, 2027

with Chris Peckover

Schedule
Tue, Thu · 8:00 to 10:00 PM ET
Included
40 live hours + 6 months of GMAT OnDemand
  • Live instruction and real-time questions
  • Class recordings and assigned practice
View class & enroll
Limited cohort · enrollment openTarget Test Prep
EALiveTeach 5 seats left
Logan Thompson
EXECUTIVE ASSESSMENT

Sep 6 to Dec 6, 2026

with Logan Thompson

Schedule
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll
Limited cohort · enrollment openTarget Test Prep
GMATOnDemand Start anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions

Compare the format, schedule, and included access before enrolling. Prices and seat counts shown reflect the supplied offer details.

The new drug Prozac and the old one Elavil are about

Expert replies
by BTGmoderatorDC » Sun May 27, 2018 12:18 am

Timer

00:00

Answers

A

B

C

D

E

Stats

Difficulty

The new drug Prozac and the old one Elavil are about equally effective in treating various forms of depression, although patients on the newer drug may have slightly fewer side effects. Thus, revenue from the sale of the new drug is going to far exceed the revenue from the sale of the old drug.

All of the following statements weaken the conclusion of the argument above, EXCEPT:

(A) Elavil is also used as a powerful anti-emetic medicine.

(B) The Drug Control Authorities in six states have refused to allow the sale of Prozac till some more tests are carried out.

(C) Some side effects of Elavil are common to Prozac as well.

(D) Prozac is not recommended as an anti-depressant for diabetics and heart patients.

(E) The unit sale price of Elavil is higher than that of Prozac.
Join the discussion
Source: — Critical Reasoning |

by deloitte247 » Wed Jun 27, 2018 11:50 am
Option A - CORRECT.
This option is almost appropriate among other options stated below. Elavil is also a strong medication used in treating various forms of depression except that its side effect is stronger than the newer drug and has reduced the rate at which it is recommended.

Option B - INCORRECT.
This statement is not proven in the researchers study stated, so therefor it is wrong.

Option C - CORRECT.
This statement is right because, according to the researcher they both have similar side effect only that Prozac as the newer one has slightly fewer side effect compared to the Elavil.

Option D - INCORRECT.
This statement may be part of the study conducted by the researcher but was not stated in the question which makes it invalid.

Option E - INCORRECT.
This option is incorrect because, it is stated in the study that the unit sale of Prozac is higher than that of Elavil.
Join the discussion